FDA Approves Enzalutamide Combined with Talazoparib for Prostate Cancer Therapy

Author: Huntsman Cancer Institute
Published: 2023/06/23 - Updated: 2023/06/27
Publication Type: Clinical Trial
Peer-Reviewed: Yes
Topic: Prostate Cancer - Publications List

Page Content: Synopsis - Introduction - Main

Synopsis: Research discovers major achievement in treatment of patients with prostate cancer and demonstrates how integration of clinical care and research directly translates into new treatment options for cancer patients. Prostate cancer is one of the most common cancers, according to the National Cancer Institute. It is also the second leading cause of cancer among men in the United States.

Introduction

"Talazoparib Plus Enzalutamide in Men With First-Line Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2): A Randomised, Placebo-Controlled, Phase 3 Trial" - The Lancet.

Neeraj Agarwal, MD, FASCO, Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, received approval by the U.S. Food and Drug Administration for a new prostate cancer treatment. This accomplishment comes shortly after he published the study in The Lancet, as the lead author, a first in institutional history.

Main Item

The new treatment combines two cancer drugs, enzalutamide and talazoparib. While enzalutamide is a medication typically used for prostate cancer, the addition of talazoparib is new in patients with prostate cancer. In a phase 3 trial, this drug combination was found to decrease the risk of cancer progression by 55%, compared to the standard treatment in these patients for whom the FDA approved the combination.

"Getting this therapy approved means improved outcomes for many people," says Agarwal. "It is validation of our unwavering commitment to create and improve cancer treatments and to relieve the suffering of our patients."

"This work, led by Dr. Agarwal, with colleagues across the world is absolutely groundbreaking," says Neli Ulrich, PhD, chief scientific officer and executive director of the Comprehensive Cancer Center at Huntsman Cancer Institute. "It will make a big difference in treatment options for many prostate cancer patients."

Prostate cancer is one of the most common cancers, according to the National Cancer Institute. It is also the second leading cause of cancer among men in the United States.

"Research at Huntsman Cancer Institute, led by Dr. Agarwal, has resulted in a major achievement in the treatment of patients with prostate cancer," says Sachin Apte, MD, MS, MBA, chief clinical officer at Huntsman Cancer Institute. "This work demonstrates how the integration of clinical care and research directly translates into new treatment options for cancer patients."

Agarwal is a dedicated researcher and clinician. As senior director for clinical research translation, he oversees many early and advanced-phase clinical trials.

Huntsman Cancer Institute at the University of Utah

Huntsman Cancer Institute at the University of Utah is the official cancer center of Utah and the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West. The institute is leading the world in scientific discovery, and turning it into unsurpassed cancer care, transforming hope into a reality.

Huntsman Cancer Institute's scientists are world renown for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient's unique tumor. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.

Huntsman Cancer Institute has over 250 research teams and 200 clinical trials open to patients. Find a clinical trial or learn more by contacting the Cancer Learning Center.

Attribution/Source(s): This peer reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by Huntsman Cancer Institute and published on 2023/06/23, this content may have been edited for style, clarity, or brevity. For further details or clarifications, Huntsman Cancer Institute can be contacted at healthcare.utah.edu/huntsmancancerinstitute/ NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Explore Similar Topics

• - This article outlines the Prostate Imaging Reporting and Data System (PI-RADS), a critical tool for evaluating prostate cancer risk.

• - This chart illustrates the different Gleason scores, their associated cancer aggressiveness, metastasis risk, and treatment considerations.

Citing and References

Founded in 2004, Disabled World (DW) is a leading resource on disabilities, assistive technologies, and accessibility, supporting the disability community. Learn more on our About Us page.

Cite This Page: Huntsman Cancer Institute. (2023, June 23 - Last revised: 2023, June 27). FDA Approves Enzalutamide Combined with Talazoparib for Prostate Cancer Therapy. Disabled World (DW). Retrieved March 20, 2025 from www.disabled-world.com/health/cancer/prostate/enzalutamide-talazoparib.php

Permalink: <a href="https://www.disabled-world.com/health/cancer/prostate/enzalutamide-talazoparib.php">FDA Approves Enzalutamide Combined with Talazoparib for Prostate Cancer Therapy</a>: Research discovers major achievement in treatment of patients with prostate cancer and demonstrates how integration of clinical care and research directly translates into new treatment options for cancer patients.

While we strive to provide accurate and up-to-date information, it's important to note that our content is for general informational purposes only. We always recommend consulting qualified healthcare professionals for personalized medical advice. Any 3rd party offering or advertising does not constitute an endorsement.